Cancer Genetics (NASDAQ:CGIX) Shares Gap Up to $0.19

Cancer Genetics Inc (NASDAQ:CGIX) gapped up before the market opened on Tuesday . The stock had previously closed at $0.21, but opened at $0.19. Cancer Genetics shares last traded at $0.18, with a volume of 16439 shares.

The company has a current ratio of 0.36, a quick ratio of 0.36 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $10.12 million, a P/E ratio of -0.28 and a beta of 1.54.

Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings data on Monday, May 20th. The medical research company reported ($0.08) EPS for the quarter. Cancer Genetics had a negative return on equity of 175.72% and a negative net margin of 77.28%. The business had revenue of $6.84 million for the quarter.

Large investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in Cancer Genetics during the first quarter worth about $48,000. Geode Capital Management LLC boosted its stake in Cancer Genetics by 106.6% during the fourth quarter. Geode Capital Management LLC now owns 221,803 shares of the medical research company’s stock worth $53,000 after acquiring an additional 114,448 shares in the last quarter. Vanguard Group Inc boosted its stake in Cancer Genetics by 119.8% during the third quarter. Vanguard Group Inc now owns 532,426 shares of the medical research company’s stock worth $554,000 after acquiring an additional 290,146 shares in the last quarter. Vanguard Group Inc. boosted its stake in Cancer Genetics by 119.8% during the third quarter. Vanguard Group Inc. now owns 532,426 shares of the medical research company’s stock worth $554,000 after acquiring an additional 290,146 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Cancer Genetics by 120.9% during the first quarter. Renaissance Technologies LLC now owns 2,007,229 shares of the medical research company’s stock worth $482,000 after acquiring an additional 1,098,515 shares in the last quarter. 10.60% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Cancer Genetics (NASDAQ:CGIX) Shares Gap Up to $0.19” was first reported by Mayfield Recorder and is owned by of Mayfield Recorder. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://mayfieldrecorder.com/2019/06/11/cancer-genetics-nasdaqcgix-shares-gap-up-to-0-19.html.

Cancer Genetics Company Profile (NASDAQ:CGIX)

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

See Also: What is a Real Estate Investment Trust (REIT)?

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.